osimertinib,lazertinib,amivantamab-vmjw
oscotec,yuhan corp,astrazeneca,genmab,janssen
['lazertinib', 'chrysalis-2']
chrysalis-2: amivantamab + lazertinib in egfr patients who progress after osi and platinum. mos 14,8m; mpfs 5,1 mo; orr 33%; mdor 9,6mo. not so bad in this setting !!!
probably a strong option. #asco22 
Head of pulmonology unit @pneumo_LS @CHUdeLyon
Professor of Pulmonology @UnivLyon1
Scientific head @URCOT_lyon & @IFCTlung
#liquidbiopsy~#screening~????